Therapeutic development for a TGF-β–conditioned, immune-excluded state in ovarian cancer should prioritize combinations that restore intratumoral CD8+ T-cell access while minimizing pathway-wide toxicities. This evidence concerns the gene CD8A and ovarian carcinoma.